Sentences with phrase «tyrosine kinase inhibitors»

33) Gandhi J, Zhang J, Xie Y, Shigematsu H, Soh J, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW, Lam WL, Garcia M, Minna JD, Gazdar AF (2009) Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

Novel drug therapies and novel indications of drug therapy, e.g. tyrosine kinase inhibitors in lung disease other than lung cancer, biological treatments for asthma, COPD, cystic fibrosis and interstitial lung disease.

First - line combination therapy with the programmed death ligand 1 (PD - L1) inhibitor avelumab and the vascular endothelial growth factor receptor tyrosine kinase inhibitor axitinib resulted in encouraging antitumor activity in patients with previously untreated renal cell carcinoma (RCC) and had a manageable toxicity profile, according to the results of the JAVELIN Renal 100 study published in Lancet Oncology.

Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.

Scanning electron micrograph of the coronary microvasculature of a mouse that has been treated with a small molecule tyrosine kinase inhibitor of platelet - derived growth factor receptor beta.

An approach often used in treating CML is to block the Bcr - Abl activity using tyrosine kinase inhibitors (TKIs).

(Moussa is listed as an inventor on a patent application that Georgetown University filed related to nilotinib and the use of other tyrosine kinase inhibitors for the treatment of neurodegenerative diseases.)

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) are teaming to revise the evidence - based guideline, «Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors.»

Updated findings from the pivotal phase II PACE trial show sustained benefit of the investigational BCR - ABL tyrosine kinase inhibitor ponatinib in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome - positive acute lymphoblastic leukemia.

Inform and educate clinicians as to updates and revisions of their Molecular testing Guideline for the Selection of Lung cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors.

«There are currently many exciting therapies including conventional chemotherapies, small molecule inhibitor tyrosine kinase inhibitors and immune modulating therapies under development in follicular lymphoma,» Westin told Cancer Network.

[13] The T315I mutation in the fusion gene confers resistance to other tyrosine kinase inhibitors such as imatinib, however axitinib has been successfully been used to treat a patient with ALL carrying this mutation, as well as CML cells in culture.

«In the near future, we'll likely see more medications specifically targeting receptors on cells involved in allergic reactions, such as tyrosine kinase inhibitors (mast cells), for dermatologic use.»

In 2004, we started looking at tyrosine kinase inhibitors, drugs that block an enzyme that fuels cell growth.

Pazopanib is a known tyrosine kinase inhibitor.

This finding is the latest from Georgetown University Medical Center's Translational Neurotherapeutics Program (TNP) examining tyrosine kinase inhibitors in the treatment of neurodegenerative diseases.

«We studied an experimental tyrosine kinase inhibitor that enters the brain and inhibits DDRs,» explains Moussa, associate professor of neurology.

The presence of a germline EGFR T790M mutation also predicts for resistance to standard tyrosine kinase inhibitors (TKIs), which adds complexity to treatment.

Importantly, in the same time our data raise concerns about ongoing clinical trials with broad spectrum tyrosine kinase inhibitors.

PHIb Trial of Fulvestrant, Palbociclib (CDK4 / 6 inhibitor) and Erdafitinib (JNJ - 42756493, pan-FGFR Tyrosine Kinase Inhibitor) in ER + / HER2 - / FGFR - amplified Metastatic Breast Cancer (MBC)

Another focus was the differential sensitivity of different mutations towards inhibition with specific tyrosine kinase inhibitors (5).

The study tested a lower dose of the oral multi-targeted tyrosine kinase inhibitor sunitinib than in previous trials, where toxicity proved too much of a problem.

Patients receiving tyrosine kinase inhibitors (TKIs) targeting EGFR mutations had a longer overall survival (OS) than those who did not receive TKIs, demonstrating the effectiveness of TKIs for LM therapy.

Despite high rates of toxicity, a first - line tyrosine kinase inhibitor / immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma.

The group identified several tyrosine kinase inhibitors that affected circadian rhythms and found evidence suggesting that the ABL (Abelson murine leukemia) and BCR (breakpoint cluster region) protein kinases are involved in the regulation of the mammalian circadian clock.

However, as proposed for the T790M mutation in the EGFR, 31 the significant gain - of - function property conferred by the mutations that we describe here may favor their initial presence before drug selection, and rapid selection during tyrosine kinase inhibitor - based therapy.

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.

Acquired resistance to anti-angiogenic tyrosine kinase inhibitors is an important clinical problem in treating various cancers.

Lydon set up the company's tyrosine kinase inhibitor program in 1986, under the direction of Alex Matter.

More recently, the chemotherapy agent melphalan has been described as having efficacy and the newer tyrosine kinase inhibitors (e.g. Palladia) may prove beneficial.

The estimation of EGFR mutation status is essential for the identification of non-small cell lung carcinoma (NSCLC) patients who may benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs), and hence for improving therapeutic efficacy.

Drugs called tyrosine kinase inhibitors (TKIs) are generally successful at controlling the cancer.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

BETHESDA, MD. — June 28, 2016 — The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised evidence - based guideline, «Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors.»

In this one hour webinar, we will review and highlight the «Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors».

However, chronic lymphocytic leukemia (CLL), which is more common in the elderly, is difficult to cure, although long - term survival has been achieved in chronic myeloid leukemia due to the introduction of tyrosine kinase inhibitors (drugs that block signals promoting cancer cell growth).

For example, epidermal growth factor (EGFR) mutations may result in sensitivity to drugs that are EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib, whereas individuals with the EGFR T790M mutation are more resistant to these drugs.

EGFR tyrosine kinase inhibitor (TKI) therapy is approved for EGFR activating mutation positive patients with advanced NSCLC, but the standard for determining mutation status is with DNA derived directly from tumor tissue, which can be limited or not available.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.

DDRs inhibition with a tyrosine kinase inhibitor appears to insulate the brain via blood - brain barrier repair, which prevents harmful immune cells that circulate in the body from getting into the brain where they can indiscriminately attack and kill healthy and sick neurons, like those that have been unable to perform autophagy to «take out their trash,» says Moussa.

If this is true, then immunocheckpoint blockade combination with EGFR tyrosine kinase inhibitors is a major path towards improving outcome of patients who have EGFR - mutant non-small-cell lung cancer.»